With a recent draft guidance from Medicare contractor Palmetto, and $6.1 million in new funding, Indi hopes to launch the test in the next six to nine months.
The firm said that it planned to lay off its oncology sales team in order to focus on women's health, despite launching an oncology business unit last spring.
Palmetto GBA has issued a draft local coverage determination for the company's Xpresys Lung 2 lung cancer test, an update version of its original Xpresys test.
Investigators explored computational strategies for identifying microRNAs that are most relevant to tumor development and progression.
The company signed separate agreements with AstraZeneca, Merck, Merck KGaA, and Pfizer to create the panel, which is expected to help speed drug development.
BMS has provided funding to the diagnostic company to support build-out of its new lab and development of its platform, which they hope can identify new biomarkers for Opdivo.
UCSF will analyze Two Pore Guys' handheld nanopore device for its ability to detect a KRAS mutation from patient blood and urine samples.
The companies plan to codevelop Adaptive's ClonoSeq assay to measure minimal residual disease in ALL.
EndoPredict is a kit-based RNA expression test that evaluates 12 genes to assess the aggressiveness of breast cancer on a molecular level, and is set to launch in the US this year.
Illumina plans to speed up the process of making Grail an independent company and will no longer have representation on its board of directors.
A subset of mutation-associated neoantigens appeared to be lost from lung or head and neck tumors that became resistant to anti-PD1 or anti-PD1 and anti-CLTA4 therapy.
The study also found that esophageal squamous cell carcinomas resemble head and neck cancer, while esophageal adenocarcinomas are similar to gastric cancers.
Both organizations plan to contribute their respective areas of expertise to work on two research projects to improve patient treatment options and outcomes.
The test combines two previously CE marked assays that are based on the company's Nucleosomics platform for identifying and quantifying nucleosome structural features.
The test screens for 90 mutations across 29 oncogenes and analyzes eight exons of three genes to help clinicians select treatments.
The researchers found preliminary evidence that some inherited cancer mutations may be more or less common in African-American women than Caucasian women.
In individuals diagnosed with prostate cancer before the age of 45, researchers saw enhanced expression of immune- and inflammation-related genes.
The researchers found that whole-genome amplification can create technical artifacts in sequence data that appear as loss-of-function indels.
A team of German researchers reported that loss-of-function mutations in FANCM were more common among cases that developed the disease at a young age.
The results indicate that while blood-based assays can be useful, tissue biopsies should remain the gold standard when available, said one of the study authors.
In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.
Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.
Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.
In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.